Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Net Margin (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Net Margin for 16 consecutive years, with 246.83% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 23760.0% to 246.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 102.04% through Dec 2025, down 9253.0% year-over-year, with the annual reading at 102.02% for FY2025, 9251.0% down from the prior year.
  • Net Margin hit 246.83% in Q4 2025 for Vanda Pharmaceuticals, down from 40.15% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 14.14% in Q2 2021 to a low of 246.83% in Q4 2025.
  • Historically, Net Margin has averaged 18.7% across 5 years, with a median of 2.46% in 2023.
  • Biggest five-year swings in Net Margin: skyrocketed 1590bps in 2023 and later plummeted -23760bps in 2025.
  • Year by year, Net Margin stood at 10.44% in 2021, then grew by 2bps to 10.68% in 2022, then crashed by -149bps to 5.28% in 2023, then plummeted by -75bps to 9.24% in 2024, then crashed by -2573bps to 246.83% in 2025.
  • Business Quant data shows Net Margin for VNDA at 246.83% in Q4 2025, 40.15% in Q3 2025, and 51.73% in Q2 2025.